Baird downgraded Immutep (IMMP) to Neutral from Outperform with a price target of $1, down from $7. The Independent Data Monitoring Committee recommended the discontinuation of the company’s pivotal TACTI-004 study in non-small cell lung cancer following the study’s planned futility analysis, the analyst tells investors in a research note. The firm is surprised by the result and does not see a clear path forward for efti.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Immutep downgraded to Market Perform from Outperform at Citizens
- Immutep Doubles Half-Year Loss as R&D Spend Rises Despite New Dr. Reddy’s Funding
- Immutep initiated with an Outperform at Citizens
- Immutep Reaches 50% Enrolment in Global Phase III Lung Cancer Trial
- Immutep achieves 50% enrollment in global TACTI-004 Phase III trial